Fierce Pharma
NOVEMBER 29, 2023
Seeking to identify ways to improve the discovery and production of medicines, Amgen is expanding its partnership with tech giant Amazon. | Amgen is growing its decade-old collaboration with Amazon Web Services—a widely used cloud platform—to create generative artificial intelligence that the companies aim to use to increase the manufacturing throughput of pharmaceuticals.
MedCity News
NOVEMBER 29, 2023
At RSNA 2023, GE HealthCare announced the launch of a new AI suite designed to simplify radiologists’ workflows when reading mammograms and help them detect breast cancer in patients sooner. The new offering includes three AI tools made by iCAD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 29, 2023
The revelation of an FDA investigation< | As industry watchers deliberate the implications from the FDA's investigation into secondary cancer risks from CAR-T medicines, an upcoming expert meeting could offer precious clarity from drug regulators.
MedCity News
NOVEMBER 29, 2023
Globally, health benefit costs are expected to increase 9.9% in 2024, according to a new report from Willis Towers Watson. This is a slightly slower pace than in 2023, which saw a record-high increase of 10.7%.
PharmExec
NOVEMBER 29, 2023
The FDA will investigate all currently approved CAR T-cell treatments, as well as BCMA-directed and CD19-directed genetically modified autologous CAR T-cell therapies, for the risk of secondary T-cell malignancies.
MedCity News
NOVEMBER 29, 2023
Medical chatbots have the potential to shape the future of healthcare data retrieval and decision-making support. But this can’t become a reality unless precautions are taken to make sure the answers are both grounded in reality and extracted from reliable sources.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 29, 2023
By streamlining front-end processes, reducing errors, and ensuring prompt service delivery, AI and automation not only boost the patient experience but also optimize revenue streams.
European Pharmaceutical Review
NOVEMBER 29, 2023
Following the US Food and Drug Administration (FDA)’s approval of Ferring Pharmaceuticals’ gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) in December 2022, new long-term follow up data has been revealed. Adstiladrin is the first FDA-approved intravesical gene therapy to be authorised for adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
MedCity News
NOVEMBER 29, 2023
For the November episode, we discuss some recent executive hires and departures occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Jeff Good, who just became Northwestern Medicine’s first chief sustainability executive.
PharmExec
NOVEMBER 29, 2023
The CDC’s Morbidity and Mortality Weekly Report show pediatric influenza hospitalization rates returned to levels that preceded the COVID-19 pandemic.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
NOVEMBER 29, 2023
Of those who have chosen ACA Marketplace coverage so far in the 2024 Open Enrollment Period, 20% are new consumers and 80% are returning consumers, according to CMS.
Pharmaceutical Technology
NOVEMBER 29, 2023
After months of negotiations, the UK's DHSC and the Association of the British Pharmaceutical Industry emerged with a plan on to replace VPAS.
pharmaphorum
NOVEMBER 29, 2023
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.
PharmaTimes
NOVEMBER 29, 2023
The new state-of-the-art facility is set to be operational in early 2024 - News - PharmaTimes
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmExec
NOVEMBER 29, 2023
Capan discusses the industry is embracing new technologies and how these use cases may evolve in the coming year.
European Pharmaceutical Review
NOVEMBER 29, 2023
For the first time, companies across the global healthcare sector, including AstraZeneca , GSK, Novo Nordisk and Roche, have united to discuss with energy providers in China and India, about scaling renewable power across their supply chains. This step is important as these countries are key markets for pharmaceuticals manufacturing. Based on data on sales/value-based shares from various companies for APIs and Chemicals, India and China are estimated to account for up to half of materials for me
Pharmaceutical Technology
NOVEMBER 29, 2023
The agency has received reports of T-cell malignancies in patients who have previously received CAR-T cell immunotherapies.
pharmaphorum
NOVEMBER 29, 2023
Karuna Therapeutics said this morning that the FDA has formally started its review of KarXT, aiming to become the first drug to reach the market for schizophrenia with a new mechanism of action in decades.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
NOVEMBER 29, 2023
Aro Biotherapeutics has raised $41.5m in a Series B financing round to advance the development of ABX1100 for Pompe disease.
pharmaphorum
NOVEMBER 29, 2023
AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a pivotal phase 2 trial.
Pharmaceutical Technology
NOVEMBER 29, 2023
Due to the increasing impact of climate change, drug packaging and shipping sectors have had to adapt by necessity.
PharmaVoice
NOVEMBER 29, 2023
U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Commerce
NOVEMBER 29, 2023
In clinical trials, KarXT (xanomeline-trospium) demonstrated a combination of strong tolerability and clinically meaningful symptom reduction in adult patients with schizophrenia.
PharmExec
NOVEMBER 29, 2023
Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for patients with severe OSA.
Pharmaceutical Technology
NOVEMBER 29, 2023
With a target of net zero for 2050, pharmaceutical companies need to tackle Scope 3 emissions, that make up the majority of their carbon footprint.
Scott’s Directories
NOVEMBER 29, 2023
The digital transformation in healthcare is not just a trend; it’s a necessary evolution. As we move further into the 21st century, the importance of data management in enhancing healthcare services cannot be overstated. This blog delves into how data management companies are revolutionizing healthcare through digital health records, focusing on the list of hospitals in Canada.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
NOVEMBER 29, 2023
GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Impetus Digital
NOVEMBER 29, 2023
Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to: Develop a b etter understanding of the current treatment landscape and lived patient experiences, including key gaps and unmet treatment needs. Design content for a virtual patient advisory board or needs assessment survey and leverage the results to educate research teams and healthcare providers on patients’ experiences and priorities.
Pharmaceutical Technology
NOVEMBER 29, 2023
GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Sales Talent
NOVEMBER 29, 2023
This question doesn’t get asked often enough and has major implications. It impacts realistic earnings projections for salespeople, what companies should expect from their new hires’ sales performance, and ultimately, salesforce turnover rates. This topic recently came up in a conversation with Shane Jamison , a tech sales coach who works with earlier stage tech companies looking to scale.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
322 
Let's personalize your content